NGM Biopharmaceuticals , Inc. (NASDAQ:NGM) reported Q4 EPS of ($0.45), $0.07 better than the analyst estimate of ($0.52). Revenue for the quarter came in at $18.18 million versus the consensus estimate of $6.77 million.
NGM Biopharmaceuticals , Inc. (NASDAQ:NGM) reported Q4 EPS of ($0.45), $0.07 better than the analyst estimate of ($0.52). Revenue for the quarter came in at $18.18 million versus the consensus estimate of $6.77 million.